BiOrion Technologies BV has raised additional funding from one of its founders for a clinical phase 2 diagnostic-imaging program in cardiac fibrosis patients.
BiOrion Technologies BV (BiOrion), a biopharmaceutical drug discovery company, develops products for diagnostic imaging and treatment of fibrosis. The company has recently finalized a first-in-human clinical PET-imaging study according to a basket design clinical study with patients suffering from organ fibrosis. It appeared that especially patients with a cardiac disease history showed a clear uptake of 68-Gallium-BOT5035 within 60 minutes after administration in typical regions of the heart whereas patients without such a cardiac disease history did not.
A second phase 2 study will be scheduled in patients with heart failure with preserved ejection fraction (HFpEF). Enrollment of patients is expected to start in H2 2022. With the additional funding we will work towards clinical proof of concept in this phase 2 study.
BiOrion is a Dutch biopharmaceutical drug discovery company involved in developing targeted therapeutics and companion imaging diagnostics for myofibroblasts-associated diseases, such as hepatic fibrosis, renal fibrosis, cardiac fibrosis, idiopathic pulmonary fibrosis and fibrosis-associated cancers such as colorectal cancer.
BiOrion’s platform and drug development engine is based on proprietary PDGFRB-binding bicyclic peptides and camelid-derived single domain antibodies. In addition to targeting to PDGFRB, the company is using its camelid-derived single domain antibody discovery engine, to extend development towards novel tracers for other myofibroblasts membrane receptors such as for PDGFRA, EGFR and IGF-1/2R. Similar to PDGFRB, these receptors are over-expressed on key pathogenic cells, although differently per fibrosis type. For more information about BiOrion: www.biorion.com
For BiOrion Technologies BV:
Herman Steen, PhD
CEO BiOrion Technologies BV